MedPath

浙江福瑞喜药业有限公司

Ownership
-
Established
2015-11-26
Employees
-
Market Cap
-
Website
http://zjfrxyy.cn/web/admin

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

5

NMPA:5

Drug Approvals

Budesonide Suspension for Inhalation

Product Name
吸入用布地奈德混悬液
Approval Number
国药准字H20244983
Approval Date
Sep 26, 2024
NMPA

Ipratropium Bromide Solution for Inhalation

Product Name
吸入用异丙托溴铵溶液
Approval Number
国药准字H20213544
Approval Date
Jun 22, 2021
NMPA

Ipratropium Bromide Solution for Inhalation

Product Name
吸入用异丙托溴铵溶液
Approval Number
国药准字H20213545
Approval Date
Jun 22, 2021
NMPA

Compound Ipratropium Bromide Solution for Inhalation

Product Name
吸入用复方异丙托溴铵溶液
Approval Number
国药准字H20213543
Approval Date
Jun 22, 2021
NMPA

Salbutamol Sulfate Solution for Inhalation

Product Name
吸入用硫酸沙丁胺醇溶液
Approval Number
国药准字H20213118
Approval Date
Feb 2, 2021
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.